Prospective, randomized, double-blind, multi-center study on 1 year course and treatment outcome under low-dose typical (haloperidol) vs. atypical neuroleptics (risperidone) in first-episode schizophrenia.
The objective of this multi-center study is to optimize the long-term treatment of patients with first episode schizophrenia. This investigation should contribute to the issue of effective relapse prevention in first-episode patients. 1-year maintenance neuroleptic treatment is done with low dose haloperidol or risperidone (target dose 2-4 mg/die).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
159
targeted dose of 2-4 mg/day over 1 year
Department of Psychiatry and Psychotherapy at the Heinrich-Heine-University
Düsseldorf, North Rhine-Westphalia, Germany
relapse rate
Time frame: 1 year
course in psychopathology
Time frame: 1 year
social and cognitive functioning
Time frame: 1 year
side-effects
Time frame: 1 year
drop-out
Time frame: 1 year
quality of life
Time frame: 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.